Summary of studies reporting the prognostic value of anti-PAD4 antibodies in RA.
| Association with Anti-PAD4 Antibodies | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Cohort | Anti-PAD4 Assay | Anti-CCP | Duration | DAS28 | HAQ | SJC | TJC | CRP | ESR | Joint Damage |
| Guderud 2018 | EURIDISS ORAR | DELFIA DELFIA | NR + | NR + | NR ± | NR – | NR ± | NR – | NR ± | NR – | NR NR |
| Navarro-Millan 2016 | CLEAR | IP | + | + | NR | NR | NR | NR | – | NR | + |
| Reyes-Castillo 2015 | JMR | ELISA | + | + | – | – | NR | NR | – | – | NR |
| Darrah 2013 | ESCAPE | IP | + | + | – | – | NR | NR | – | NR | + |
| Kolfenbach 2010 | Pre-RA | IP | + | NR | NR | NR | NR | NR | NR | NR | NR |
| Harris 2008 | ESCAPE | IP | + | + | NR | NR | NR | NR | NR | NR | + |
| Halvorsen 2008 | EURIDISS ORAR | ELISA ELISA | + + | + + | NR | NR + | NR + | NR – | + + | – – | NR + |
| Zhao 2008 | PUPH | ELISA | + | NR | + | NR | NR | NR | – | + | + |
+: yes; –: no; ±: associated in univariate but not multivariate models. RA: rheumatoid arthritis; anti-CCP: anticyclic citrullinated peptide antibodies; DAS28: 28-joint count Disease Activity Score; HAQ: Health Assessment Questionnaire; SJC: swollen joint count; TJC: tender joint count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DELFIA: dissociation-enhanced lanthanide fluorescence immunoassay; EURIDISS: European Research on Incapacitating Disease and Social Support; ORAR: Oslo RA Register; CLEAR: Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis; JMR: Jalisco, Mexico Rheumatology; ESCAPE: Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis; PUPH: Peking University People’s Hospital; NR: not reported; anti-PAD4: antipeptidyl arginine deiminase type 4; IP: immunoprecipitation.